Treating patients with overactive bladder syndrome with antimuscarinics: Heart rate considerations

BJU International

Volumn 100, Issue 5, 2007, Pages 1007-1014

  Andersson, Karl Erik ^a   Olshansky, Brian ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Antimuscarinics; Cardiac disease; Heart rate; Muscarinic receptors; Overactive bladder

Indexed keywords

ATROPINE; MUSCARINIC RECEPTOR BLOCKING AGENT; TERODILINE;

ADRENERGIC SYSTEM; AGE DISTRIBUTION; AGING; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLINERGIC SYSTEM; COMORBIDITY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENDER; HEART ARRHYTHMIA; HEART ATRIOVENTRICULAR NODE; HEART DEPOLARIZATION; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOWER URINARY TRACT SYMPTOM; NONHUMAN; OVERACTIVE BLADDER; OXYGEN CONSUMPTION; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRESSORECEPTOR REFLEX; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; SHORT SURVEY; SYMPATHETIC TONE; TACHYCARDIA; TORSADE DES POINTES; URINE INCONTINENCE; VAGUS NERVE STIMULATION;

CARDIOVASCULAR DISEASES; HEART RATE; HUMANS; MUSCARINIC ANTAGONISTS; URINARY BLADDER, OVERACTIVE;

EID: 35148812233     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07100.x     Document Type: Short Survey

References (79)

1. Andersson KE, Appell R, Cardozo L et al. Pharmacological treatment of urinary incontinence. In : Abrams P, Cardozo L, Khoury S, Wein, A eds, Incontinence (3rd International Consultation on Incontinence). France : Health Publication Ltd, 2005 : 811 54
2. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003 61 : 37 49
3. Khullar V, Chapple C, Gabriel Z, Dooley JA. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 2006 68 (Suppl. 38 48
4. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006 4 : CD003781
5. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993 3 : 335 48
6. Stewart DA, Taylor J, Ghosh S et al. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 1992 42 : 577 80
7. Kay G, Crook T, Rekeda L et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006 50 : 317 26
8. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004 350 : 1013 22
9. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006 440 : 463 9
10. Tristani-Firouzi M. Andersen-Tawil syndrome: an ever-expanding phenotype? Heart Rhythm 2006 3 : 1351 2
11. Habib G. Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality. Clin Ther 1997 19 (Suppl. A 39 52
12. Singh B. Increased heart rate as a risk factor for cardiovascular disease. Eur Heart J Suppl 2003 5 (Suppl. G G3 G9
13. Palatini P, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens 2004 26 : 637 44
14. Lanza GA, Fox K, Crea F. Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing. Adv Cardiol 2006 43 : 1 16
15. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 20 : 327 36
16. Corcos J, Schick E. Prevalence of overactive bladder and incontinence in Canada. Can J Urol 2004 11 : 2278 84
17. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 87 : 760 6
18. Temml C, Heidler S, Ponholzer A, Madersbacher S. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol 2005 48 : 622 7
19. Homma Y, Yamaguchi O, Hayashi K Neurogenic Bladder Society Committee. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int 2005 96 : 1314 8
20. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006 50 : 1306 15
21. Monz B, Chartier-Kastler E, Hampel C et al. Patient characteristics associated with quality of life in European women seeking treatment for urinary incontinence: results from PURE. Eur Urol 2007 51 : 1073 82
22. Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc 2006 54 : 1516 23
23. Loffelholz K, Pappano AJ. The parasympathetic neuroeffector junction of the heart. Pharmacol Rev 1985 37 : 1 24
24. De Meersman RE, Stein PK. Vagal modulation and aging. Biol Psychol 2007 74 : 165 73
25. Seals DR, Monahan KD, Bell C, Tanaka H, Jones PP. The aging cardiovascular system: changes in autonomic function at rest and in response to exercise. Int J Sport Nutr Exerc Metab 2001 11 (Suppl. S189 95
26. Satoh H. Sino-atrial nodal cells of mammalian hearts: ionic currents and gene expression of pacemaker ionic channels. J Smooth Muscle Res 2003 39 : 175 93
27. Levy MN. Autonomic interactions in cardiac control. Ann NY Acad Sci 1990 601 : 209 21
28. Uijtdehaage SH, Thayer JF. Accentuated antagonism in the control of human heart rate. Clin Auton Res 2000 10 : 107 10
29. Mensink GB, Hoffmeister H. The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. Eur Heart J 1997 18 : 1404 10
30. Palatini P, Benetos A, Grassi G et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006 24 : 603 10
31. Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol 2007 74 : 224 42
32. Palatini P, Thijs L, Staessen JA et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002 162 : 2313 21
33. Goldberger JJ, Le FK, Lahiri M, Kannankeril PJ, Ng J, Kadish AH. Assessment of parasympathetic reactivation after exercise. Am J Physiol Heart Circ Physiol 2006 290 : H2446 52
34. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005 352 : 1951 8
35. Falcone C, Buzzi MP, Klersy C, Schwartz PJ. Rapid heart rate increase at onset of exercise predicts adverse cardiac events in patients with coronary artery disease. Circulation 2005 112 : 1959 64
36. Leeper NJ, Dewey FE, Ashley EA et al. Prognostic value of heart rate increase at onset of exercise testing. Circulation 2007 115 : 468 74
37. Chaitman BR. Should early acceleration of heart rate during exercise be used to risk stratify patients with suspected or established coronary artery disease? Circulation 2007 115 : 430 1
38. Elghozi JL, Girard A, Laude D. Effects of drugs on the autonomic control of short-term heart rate variability. Auton Neurosci 2001 90 : 116 21
39. Kleiger RE, Stein PK, Bigger JT Jr. Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol 2005 10 : 88 101
40. Scheinin H, Helminen A, Huhtala S et al. Spectral analysis of heart rate variability as a quantitative measure of parasympatholytic effect - integrated pharmacokinetics and pharmacodynamics of three anticholinergic drugs. Ther Drug Monit 1999 21 : 141 51
41. Penttila J, Kuusela T, Scheinin H. Analysis of rapid heart rate variability in the assessment of anticholinergic drug effects in humans. Eur J Clin Pharmacol 2005 61 : 559 65
42. Penttila J, Vesalainen R, Helminen A et al. Spontaneous baroreflex sensitivity as a dynamic measure of cardiac anticholinergic drug effect. J Auton Pharmacol 2001 21 : 71 8
43. Choi JB, Kim YB, Kim BT, Kim YS. Analysis of heart rate variability in female patients with overactive bladder. Urology 2005 65 : 1109 13
44. La Rovere MT, Bigger JT Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone Reflexes After Myocardial Infarction) Investigators. Lancet 1998 351 : 478 84
45. La Rovere MT, Pinna GD, Hohnloser SH et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 2001 103 : 2072 7
46. Johansson M, Gao SA, Friberg P et al. Baroreflex effectiveness index and baroreflex sensitivity predict all-cause mortality and sudden death in hypertensive patients with chronic renal failure. J Hypertens 2007 25 : 163 8
47. Dhein S, van Koppen CJ, Brodde OE. Muscarinic receptors in the mammalian heart. Pharmacol Res 2001 44 : 161 82
48. 3 muscarinic acetylcholine receptors in mammalian hearts. Br J Pharmacol 2004 142 : 395 408
49. Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci 2006 100 : 323 37
50. Caulfield MP. Muscarinic receptors - characterization, coupling and function. Pharmacol Ther 1993 58 : 319 79
51. 3 receptors. Auton Autacoid Pharmacol 2007 27 : 1 11
52. 2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 1999 96 : 1692 7
53. Stengel PW, Gomeza J, Wess J, Cohen ML. M(2) and M(4) receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J Pharmacol Exp Ther 2000 292 : 877 85
54. Stengel PW, Yamada M, Wess J, Cohen ML. M(3)-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea. Am J Physiol Regul Integr Comp Physiol 2002 282 : R1443 9
55. 5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Receptors Channels 2003 9 : 279 90
56. 3 receptor subtype gene expression in the human heart. Cell Mol Life Sci 2000 57 : 175 80
57. Wang H, Han H, Zhang L et al. Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. Mol Pharmacol 2001 59 : 1029 36
58. Krejci A, Tucek S. Quantitation of mRNAs for M(1) to M(5) subtypes of muscarinic receptors in rat heart and brain cortex. Mol Pharmacol 2002 61 : 1267 72
59. 3-muscarinic receptors in the human heart. Naunyn Schmiedebergs Arch Pharmacol 2003 368 : 316 9
60. 1 receptor activation reduces maximum upstroke velocity of action potential in mouse right atria. Eur J Pharmacol 1998 346 : 227 36
61. Colecraft HM, Egamino JP, Sharma VK, Sheu SS. Signaling mechanisms underlying muscarinic receptor-mediated increase in contraction rate in cultured heart cells. J Biol Chem 1998 273 : 32158 66
62. 3 muscarinic acetylcholine receptors in human atrial myocytes: influence of chronic atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol 2003 267 (Suppl. 1 R94
63. Hardouin SN, Richmond KN, Zimmerman A, Hamilton SE, Feigl EO, Nathanson NM. Altered cardiovascular responses in mice lacking the M(1) muscarinic acetylcholine receptor. J Pharmacol Exp Ther 2002 301 : 129 37
64. 4-receptor-deficient mice. Br J Pharmacol 2003 138 : 469 80
65. Nishimaru K, Tanaka Y, Tanaka H, Shigenobu K. Positive and negative inotropic effects of muscarinic receptor stimulation in mouse left atria. Life Sci 2000 66 : 607 15
66. 3-muscarinic receptors in ventricular cardiomyocytes of adult rats. Br J Pharmacol 2003 138 : 156 60
67. Niihashi M, Esumi M, Kusumi Y, Sato Y, Sakurai I. Expression of muscarinic receptor genes in the human coronary artery. Angiology 2000 51 : 295 300
68. Konidala S, Gutterman DD. Coronary vasospasm and the regulation of coronary blood flow. Prog Cardiovasc Dis 2004 46 : 349 73
69. Yasue H, Horio Y, Nakamura N et al. Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 1986 74 : 955 63
70. Choi SS, Lim YJ, Bahk JH, Do SH, Ham BM. Coronary artery spasm induced by carotid sinus stimulation during neck surgery. Br J Anaesth 2003 90 : 391 4
71. 3 receptors in response to acetylcholine. Arterioscler Thromb Vasc Biol 2004 24 : 1253 8
72. Gillum RF. The epidemiology of resting heart rate in a national sample of men and women: associations with hypertension, coronary heart disease, blood pressure, and other cardiovascular risk factors. Am Heart J 1988 116 : 163 74
73. Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993 125 : 1148 54
74. Kannel WB, Wilson P, Blair SN. Epidemiological assessment of the role of physical activity and fitness in development of cardiovascular disease. Am Heart J 1985 109 : 876 85
75. Wilhelmsen L, Berglund G, Elmfeldt D et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur Heart J 1986 7 : 279 88
76. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997 15 : 3 17
77. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J 1991 121 : 172 7
78. Hjalmarson A, Gilpin EA, Kjekshus J et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990 65 : 547 53
79. Aronow WS, Ahn C, Mercando AD, Epstein S. Association of average heart rate on 24-hour ambulatory electrocardiograms with incidence of new coronary events at 48-month follow-up in 1,311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol 1996 78 : 1175 6